ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PRME / earnings
MGTX (20) GLUE (25) ODTX (46) SANA (33) ⌘ Pro Terminal →

Prime Medicine Inc. (PRME) Next Earnings Date & Expected ±12.5% Move

$4.44 -5.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.38

Prime Medicine Inc. (PRME) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $856.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRME Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRME stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Prime Medicine Inc. (NASDAQ: PRME) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.44 (-5.93% 1D, market cap $856.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRME ranks #789 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRME compare to MGTX and GLUE in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PRME carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGTX (MeiraGTx Holdings plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $911.4M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M). Among the 5-stock peer group, PRME leads on earnings multiple (N/A) while PRME leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRME?
▼

Per PRME's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894562), Prime Medicine Inc. generated $4.6M in revenue (+55.3% YoY), -$201.1M in net income, and -$167.1M in free cash flow against $342.7M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.38 (-1.26%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk E
Cash (3)Whales (16)SEC (3)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$6 Bull$4 Base$3 Bear
📬 FREE PRME RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRME)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY PRME SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (53% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 55% of 52W Range • RSI-14 at 58.5 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
22
Grade E$3.32+18.1% Next Q
Q2 (-2Q)
25
Grade E$3.92+11% Next Q
Q3 (-1Q)
27
Grade E$4.35+2.1% Next Q
Current
30
Grade E$4.44-9.6% Hist 90D α
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRME Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRME currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.60) and Max Pain ($4.66) forces dealer call-delta covering toward $6.21.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRME• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRME Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.56 Expected Swing
$3.88 (-12.5%)Spot $4.44$5.00 (+12.5%)
MODEL EARNINGS SETUP GAUGE

PRME Quantitative Pre-Earnings Setup: 30/100

Trailing EPS: $4.25 • YoY Revenue Growth: 55.3%

Model Bullish Setup (30/100)Model Risk Weight (70/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$4.6M-$201.1M-$167.1M52%
FY 20242024-12-31$3.0M-$195.9M-$130.2M52%
FY 20232023-12-31$573.4M-$198.1M-$165.4M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRME)

  • ✓Walkthrough of PRME's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PRME // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +27.95%▲ ASCENDING CHANNEL
2026-11-03O $5.24H $5.24L $4.44C $4.44VOL 6.57M
RES: $5.95SUP: $2.80SMA50: $3.60SMA200: $3.50
$6.14$5.20$4.26$3.32$2.38RES $5.95SUP $2.80$4.442026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRME Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRME Butterfly Map → + Track PRME →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +55.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PRME today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRME. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRME today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRME)

Health Care Rank #789 of 1015 ⚔️ MGTX vs PRME Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRME vs. MGTX, GLUE, ODTX, SANA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Prime Medicine Inc. (PRME) ranks #789 by composite RQD confidence (30/100, grade E) and #378 by equity capitalization ($856.1M). Within this direct 5-issuer industry benchmark cohort, PRME leads on earnings valuation at N/A trailing P/E, while PRME leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with PRME at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRME ACTIVE
Prime Medicine Inc.
E 30/100 — — -35.0% -5.93% $856.1M Benchmark Subject
MGTX
MeiraGTx Holdings plc
E 20/100 — — -35.0% -1.79% $911.4M /mgtx-vs-prme →
GLUE
Monte Rosa Therapeutics Inc.
E 25/100 — — -35.0% -1.21% $918.0M /glue-vs-prme →
ODTX
Odyssey Therapeutics Inc.
D 46/100 — — — -0.05% $939.1M /odtx-vs-prme →
SANA
Sana Biotechnology Inc.
E 33/100 — — -35.0% -6.61% $769.4M /sana-vs-prme →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001894562 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prime Medicine Inc. (PRME) reported GAAP revenue of $4.6M (+55.3% vs. FY2024 revenue of $3.0M , and -99.2% cumulative change since FY2023) , GAAP net income of -$201.1M, operating cash flow of -$162.6M, and free cash flow of -$167.1M (-28.4% YoY). On the balance sheet, PRME closed FY2025 with $342.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.6M -$201.1M -$162.6M -$167.1M $342.7M —
FY2024 (FY) 2024-12-31 $3.0M -$195.9M -$122.9M -$130.2M $297.5M —
FY2023 (FY) 2023-12-31 $573.4M -$198.1M -$165.4M -$165.4M — —

3. PRME Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRME stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Prime Medicine Inc. (NASDAQ: PRME) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.44 (-5.93% 1D, market cap $856.1M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRME ranks #789 in composite RQD confidence.

How does PRME compare to MGTX and GLUE in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PRME carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGTX (MeiraGTx Holdings plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $911.4M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M). Among the 5-stock peer group, PRME leads on earnings multiple (N/A) while PRME leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRME?

Per PRME's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894562), Prime Medicine Inc. generated $4.6M in revenue (+55.3% YoY), -$201.1M in net income, and -$167.1M in free cash flow against $342.7M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRME trading relative to its 50-day, 200-day, and 52-week technical levels?

PRME last traded at $4.44 (-5.93% on volume of 4,124,841 shares), positioning the stock +23.33% above its 50-day simple moving average ($3.60) and +26.86% above its 200-day simple moving average ($3.50). Across its 52-week range of $2.67 to $5.91, PRME sits at the 54.6% percentile with a 14-day RSI of 58.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($3.88 to $5.00).

Direct Sub-Reports: PRME RQD Cockpit PRME 12M Forecast PRME Earnings & Move PRME Dividends & DRIP PRME Insiders & 13F PRME Whale Options PRME Profit Sankey PRME News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

PRME — Prime Medicine Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Prime Medicine Inc. (PRME) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.44 (-5.93% 1D, market capitalization $856.1M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -17.58%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Prime Medicine Inc. (PRME) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Its market capitalization is $1.0B. Reported FY 2025 revenue was $4.6M against an operating loss of -$208.3M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Prime Medicine Inc. (PRME) reported $4.6M in annual revenue (up from $3.0M in FY2024, +55.3% YoY) and -$201.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($573.4M revenue, -$198.1M net income) through FY2025, PRME scaled operating cash flow to -$162.6M and free cash flow to -$167.1M, backed by $342.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -17.58% and institutional whale pillar of 16/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $2.67 – $5.91 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated dependencies. A prospective investor should note that this absence is itself a data limitation rather than evidence of independence, since the graph contains no entries. Sector context is limited to the Health Care / Biological Products classification and the beta of 1.0 per the market data.

  • Key Question #1: Can PRME sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.6M and free cash flow of -$167.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PRME's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PRME Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Prime Medicine Inc. (PRME) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRME Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRME Bull vs. Bear Conversation Board — What's Your Call at $4.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRME 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PRME:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $5.43 (+15.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 17/20 in the RQD rating, the strongest pillar, alongside a recent rally of nea

Institutional accumulation and options positioning score 17/20 in the RQD rating, the strongest pillar, alongside a recent rally of nearly 26% in a month.. When you look under the hood at PRME, Fundamental Cash Engine is 2/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $5.91. My 12M target is $5.43.

ArenaChamp_24 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $4.01 (-15.0%)
Spot @ $4.72

Operating margin of -60%, FCF yield of -17.58%, Altman Z of 0.2, and cash falling from $182.5M to $63.0M leave the company with weak ca

Operating margin of -60%, FCF yield of -17.58%, Altman Z of 0.2, and cash falling from $182.5M to $63.0M leave the company with weak cash generation and elevated distress risk.. Look at the math on PRME: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $4.15 before getting long.

LIVE TAPE